Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA

MILWAUKEE, April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating Kintara (Nasdaq: KTRA) for possible breaches of fiduciary duty and other violations of law in its transaction with TuHURA.

Click here to learn how to join the https://www.ademilaw.com/case/kintara-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Kintara stockholders will own approximately 2.85% of the combined company (or 5.45% of the combined company after giving effect to the issuance of the CVR Shares) and TuHURA equityholders would own approximately 97.15% of the combined company on an "as converted" to Kintara Common Stock basis (or 94.55% of the combined company after giving effect to the issuance of the CVR Shares). Officers and directors of Kintara have entered into support agreements with Kintara and TuHURA to vote all of their shares of capital stock of Kintara in favor of the transaction and against any alternative acquisition proposals. Kintara insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Kintara's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Kintara common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/kintara-therapeutics-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP